focus -WSS

focus

author：Wikipedia 2025-09-03 11:46:53 - browse：97352

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： FogPharma raises $145 million in rare Series E round

focus

WSS

Medical school prerequisites are outdated

RSV vaccines may be linked to small increased risk of developing GBS

NIH chief: government has fallen behind pharma on clinical trials

Scientists unlock the key to scar

Flu vaccine offering decent levels of protection this winter, new data show

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

hotspot

focus

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Medical device lobby: We're tired of waiting on Medicare coverage

Sports medicine is finally prioritizing gender equality

Weight loss drugs should be covered by insurers, AMA says

In Memoriam: Notable people who died in 2023

After decades in use, heart stents finally beat placebo

Medicare proposal to cover medical devices draws a mixed reaction

RSV vaccines may be linked to small increased risk of developing GBS

In age of alternative facts, a scholarly course on calling out crap

Pfizer highlights cancer drugs it thinks could reignite investor interest

focus

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Pfizer highlights cancer drugs it thinks could reignite investor interest

What health policies could hitch a ride on a spending bill?

FDA does about

Type 2 diabetes prevention programs work at large scale: study

Change Healthcare cyberattack outage could last weeks

focus

entertainment

focus

hotspot